MedKoo product information:

 Vindesine

vindesine is a synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

 1: Smith V, Dai F, Spitz M, Peters GJ, Fiebig HH, Hussain A, Burger AM. Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother. 2009 Nov;21(5):542-9. PubMed PMID: 19933046.

2: Takigawa N, Tanimoto M. [Vinca alkaloid and MDR1]. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9. Japanese. PubMed PMID: 18633246.

3: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

4: Pearce HL, Alice Miller M. The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul. 2005;45:229-55. Epub 2005 Sep 6. PubMed PMID: 16143373.

5: Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H, Ohnoshi T, Tanimoto M. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res. 2004 Nov-Dec;24(6):3911-6. PubMed PMID: 15736431.

6: Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004 Jan 15;22(2):254-61. PubMed PMID: 14722033.

7: Sinha P, Poland J, Kohl S, Schnölzer M, Helmbach H, Hütter G, Lage H, Schadendorf D. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis. 2003 Jul;24(14):2386-404. PubMed PMID: 12874874.

8: Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents. 2002 Jan;2(1):55-70. Review. PubMed PMID: 12678751.

9: Prignano F, Coronnello M, Pimpinelli N, Cappugi P, Mini E, Giannotti B. Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. Cancer Lett. 2002 Dec 5;186(2):183-92. PubMed PMID: 12213288.

10: Poland J, Schadendorf D, Lage H, Schnölzer M, Celis JE, Sinha P. Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med. 2002 Mar;40(3):221-34. Review. PubMed PMID: 12005211.

11: Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release. 2002 Apr 23;80(1-3):29-44. PubMed PMID: 11943385.

12: Sakaki Y, Terashi K, Yamaguchi A, Kawamata N, Tokito Y, Mori H, Umehara M, Yoshiyama T, Ohtsubo H, Arimura K, Arima N, Tei C. Human T-cell lymphotropic virus type I Tax activates lung resistance-related protein expression in leukemic clones established from an adult T-cell leukemia patient. Exp Hematol. 2002 Apr;30(4):340-5. PubMed PMID: 11937269.

13: Yano S, Sone S. [Treatment for elderly lung cancer patients by anticancer drugs and possible use of target based drugs]. Nippon Ronen Igakkai Zasshi. 2001 May;38(3):317-9. Japanese. PubMed PMID: 11431880.

14: Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marié FN, Benmiloud M, Sturtz F. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol. 2000 Nov;11(11):1471-6. PubMed PMID: 11142488.

15: Ohi Y, Kim R, Toge T. Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells. Int J Oncol. 2000 May;16(5):959-69. PubMed PMID: 10762632.

16: Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, Yatsugi H, Yamauchi K. An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J. 1999;46(3-4):163-6. PubMed PMID: 10659592.

17: Hamada K, Mikasa K, Yunou Y, Kurioka T, Majima T, Narita N, Kita E. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy. 2000 Jan-Feb;46(1):49-61. PubMed PMID: 10601798.

18: Morikawa N, Mori T, Kamenofuchi Y, Kawashima H, Takeyama M, Hori S. Dose-related increases in cerebrospinal fluid concentrations of methotrexate in a postoperative patient with glioblastoma. Ann Pharmacother. 1999 Sep;33(9):952-6. PubMed PMID: 10492499.

19: Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Schweigert M, Stuschke M, Fleischhacker M, Siebert G, Mergenthaler HG, Werner TG, Sezer O, Possinger K. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy? Eur J Med Res. 1999 Aug 25;4(8):328-34. PubMed PMID: 10471544.

20: Słowik-Gabryelska A, Szczepanik A, Kalicka A. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients]. Pol Merkur Lekarski. 1999 Jan;6(31):18-22. Polish. PubMed PMID: 10344148.

21: Sunami T, Nishio K, Kanzawa F, Fukuoka K, Kudoh S, Yoshikawa J, Saijo N. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. Cancer Chemother Pharmacol. 1999;43(5):394-401. PubMed PMID: 10100595.

22: Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N, Ueyama Y. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol. 1998 Nov;11(11):1059-63. PubMed PMID: 9831202.

23: Pereira E, Tarasiuk J, Garnier-Suillerot A. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids. Chem Biol Interact. 1998 Jul 3;114(1-2):61-76. PubMed PMID: 9744556.

24: Higashiyama M, Kodama K, Yokouchi H, Takami K, Doi O, Kobayashi H, Tanisaka K, Minamigawa K. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol. 1998 May;68(1):19-24. PubMed PMID: 9610658.

25: Morikawa N, Mori T, Takeyama M, Hori S. Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. Biol Pharm Bull. 1998 Mar;21(3):297-9. PubMed PMID: 9556164.

26: Geldof AA, Minneboo A, Heimans JJ. Vinca-alkaloid neurotoxicity measured using an in vitro model. J Neurooncol. 1998 Apr;37(2):109-13. PubMed PMID: 9524088.

27: Mizushima Y, Li H, Sassa K, Fujishita T, Oosaki R, Kobayashi M. Grouping of anticancer drugs based on administration method-related toxicity patterns in rats. Anticancer Res. 1997 Nov-Dec;17(6D):4611-4. PubMed PMID: 9494577.

28: Ishihama H, Nagai S, Umezu H, Ikeda Y, Sugita K, Kobayashi S, Chimoto M, Shimada K. [The usefulness of fibrin glue spraying combined with CDDP for lung cancer]. Gan To Kagaku Ryoho. 1997 Jun;24(8):981-5. Japanese. PubMed PMID: 9212808.

29: Navarra P, Preziosi P. Disruptions of the hypothalamo-pituitary-adrenal axis increase anticancer drug lethality in the rat. Toxicol Lett. 1997 May 16;91(3):219-27. PubMed PMID: 9217242.

30: Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-8-S7-16. PubMed PMID: 9194474.

31: Kobayashi S, Okada S, Yoshida H, Fujimura S. Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells. Tohoku J Exp Med. 1997 Mar;181(3):361-70. PubMed PMID: 9163851.

32: Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 1996 Nov-Dec;16(6B):3387-95. PubMed PMID: 9042196.

33: Takeda S, Ikeba K, Ohokubo T, Sodemoto T, Yamamoto T, Takagi A, Hayashi N, Kinoshita K. [Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy]. Gan To Kagaku Ryoho. 1996 Oct;23(12):1697-703. Japanese. PubMed PMID: 8886048.

34: Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer. 1996 Jun;14(2-3):301-14. PubMed PMID: 8794412.

35: Djuanda I, Depenbrock H, Peter R, Block T, Pohlmann G, Rastetter J, Hanauske AR. Efficacy of 5'-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro. Invest New Drugs. 1996;14(2):153-9. PubMed PMID: 8913836.

36: Saijo N, Nishio K, Ohta S, Arioka H, Funayama Y, Fukuoka K, Kurokawa H, Nomoto T, Ishida T, Yamamoto N, Tamura T, Shinkai T, Eguchi K, Ohe Y, Kunito H, Ohtsu T, Sasaki Y. Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Cancer Chemother Pharmacol. 1996;38 Suppl:S11-5. Review. PubMed PMID: 8765409.

37: Cipolla B, Blanchard Y, Chamaillard L, Quemener V, Guillé F, Havouis R, Moulinoux JP. In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Urol Res. 1996;24(2):93-8; discussion 99. PubMed PMID: 8740978.

38: Pauwels O, Kiss R, Pasteels JL, Atassi G. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents. J Pharm Pharmacol. 1995 Oct;47(10):870-5. PubMed PMID: 8583358.

39: Licht T, Lübbert M, Martens C, Bross KJ, Fiebig HH, Mertelsmann R, Herrmann F. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. Cytokines Mol Ther. 1995 Jun;1(2):123-32. Erratum in: Cytokines Cell Mol Ther 1997 Dec;3(4):282-3. PubMed PMID: 9384669.

40: Ando N, Ozawa S, Kitajima M, Iizuka T. [Chemotherapy and multimodality therapy in the treatment of esophageal cancer]. Gan To Kagaku Ryoho. 1995 Jun;22(7):869-76. Review. Japanese. PubMed PMID: 7540823.

41: Inoue T, Ishida T, Sugio K, Maehara Y, Sugimachi K. Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration. 1995;62(4):223-7. PubMed PMID: 8578019.

42: Koga K, Iizuka E, Sato A, Ekimoto H, Okada M. Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Cancer Chemother Pharmacol. 1995;36(6):459-62. PubMed PMID: 7554036.

43: Saito T, Hikita M, Kohno K, Tanimura H, Miyahara M, Kobayashi M. Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology. 1994 Sep-Oct;51(5):440-5. PubMed PMID: 8052486.

44: Malgrange B, Delrée P, Rigo JM, Baron H, Moonen G. Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods. 1994 Jul;53(1):111-22. PubMed PMID: 7990508.

45: Uchida J, Satake H, Saito H, Nakano K, Takeda S, Unemi N. [Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer]. Gan To Kagaku Ryoho. 1994 Jun;21(7):1001-8. Japanese. PubMed PMID: 8210249.

46: Lévi F. Chronotherapy of cancer: biological basis and clinical application. Pathol Biol (Paris). 1994 Apr;42(4):338-41. Review. PubMed PMID: 7808787.

47: Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res. 1994 Mar;85(3):290-7. PubMed PMID: 7514586.

48: Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y, et al. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol. 1994;34 Suppl:S112-7. Review. PubMed PMID: 8070019.

49: Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 1993 Nov 1;53(21):5121-6. PubMed PMID: 8221648.

50: Kakegawa T, Yamana H, Fujita H, Shinozaki K. [Surgical adjuvant therapy of carcinoma of the thoracic esophagus]. Gan To Kagaku Ryoho. 1993 Jul;20(9):1173-8. Japanese. PubMed PMID: 8333745.

51: Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61. PubMed PMID: 8452560.

52: Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindeløv L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer. 1993 Feb;67(2):311-20. PubMed PMID: 8094293; PubMed Central PMCID: PMC1968190.

53: Kubota R, Kubota K, Yamada S. [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2163-7. Japanese. PubMed PMID: 1444481.

54: Nagata S, Masuda K, Nogusa H, Hirano K, Takagishi Y. New application of human tumor clonogenic assay to in vitro evaluation of tumor-targeting efficiency of immunoconjugates. Chem Pharm Bull (Tokyo). 1992 Aug;40(8):2151-4. PubMed PMID: 1423771.

55: Furuse K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A, Yamaguchi Y. [A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)]. Gan To Kagaku Ryoho. 1992 Jul;19(7):1019-26. Japanese. PubMed PMID: 1320846.

56: Hirabayashi M, Tanaka Y, Yoshida H, Nakagawa M, Kawakami K, Mishima M, Kuno K. [Evaluation of chemotherapy of unresectable non-small cell lung cancer]. Gan To Kagaku Ryoho. 1992 Jan;19(1):55-60. Japanese. PubMed PMID: 1309632.

57: Iwasaki H, Fukushima T, Uchida M, Ueda T, Nakamura T, Ishiguro K, Ueda K, Takada N. [Hospital spread of scabies from an immunocompromised patient with Norwegian scabies]. Kansenshogaku Zasshi. 1991 Sep;65(9):1194-9. Japanese. PubMed PMID: 1761899.

58: Adachi I, Watanabe T, Suzuki M, Tsuchihashi T, Yin DF, Yamaguchi K, Abe K. Effects of continuous vindesine administration of advanced breast cancer resistant to chemotherapy including adriamycin. Jpn J Clin Oncol. 1991 Jun;21(3):180-7. PubMed PMID: 1942549.

59: Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. [Combined effect of HO-221 with various antitumor agents against L 1210 leukemia]. Gan To Kagaku Ryoho. 1991 Apr;18(4):555-62. Japanese. PubMed PMID: 2012397.

60: Mizushima Y, Konishi K, Morikage T, Yano S. Importance of administration method in high-dose anticancer chemotherapy from toxicological standpoint in rats. Oncology. 1991;48(5):431-7. PubMed PMID: 1720885.

61: Mizushima Y, Morikage T, Kuwahara T, Yano S. Effects of granulocyte colony-stimulating factor on hematopoietic injury induced by anticancer drugs in mice. J Biol Response Mod. 1990 Dec;9(6):576-83. PubMed PMID: 1705961.

62: Kiue A, Sano T, Naito A, Inada H, Suzuki K, Okumura M, Kikuchi J, Sato S, Takano H, Kohno K, et al. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro. Jpn J Cancer Res. 1990 Oct;81(10):1057-64. PubMed PMID: 1977728.

63: Berger DP, Henss H, Winterhalter BR, Fiebig HH. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann Oncol. 1990 Sep;1(5):333-41. PubMed PMID: 2261375.

64: Ikushima S, Fujiwara F, Todo S, Imashuku S. Gamma linolenic acid alters the cytotoxic activity of anticancer drugs on cultured human neuroblastoma cells. Anticancer Res. 1990 Jul-Aug;10(4):1055-9. PubMed PMID: 2166461.

65: Shibuya M, Hirosawa A, Niitani H. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy]. Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 2):950-6. Review. Japanese. PubMed PMID: 2111664.

66: Mizushima Y, Morikage T, Yano S. Differences in in vitro proliferative responsiveness to granulocyte colony-stimulating factor and interleukin 2 of bone marrow cells from mice treated with chemotherapeutic drugs. Cancer Res. 1990 Mar 15;50(6):1847-52. PubMed PMID: 1689612.

67: Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H. Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. Eur J Cancer. 1990;26(8):898-901. PubMed PMID: 2145935.

68: Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K, Tsuruo T, Shimoyama M. Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16. Jpn J Cancer Res. 1989 Oct;80(10):1006-13. PubMed PMID: 2575608.

69: Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res. 1989 Aug 1;49(15):4098-102. PubMed PMID: 2472873.

70: Lindén CJ. Toxicity of intraperitoneally administered antitumour drugs in athymic rats. In Vivo. 1989 Jul-Aug;3(4):259-62. PubMed PMID: 2519862.

71: Beijnen JH, Vendrig DE, Underberg WJ. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol. 1989 Mar-Apr;43(2):84-7. PubMed PMID: 2709240.

72: Preziosi P, Vacca M, Ragazzoni E, del Carmine R, Navarra P. Stress hormone changes after toxic doses of new anticancer drugs. Arch Toxicol Suppl. 1989;13:436-9. PubMed PMID: 2549916.

73: Takada M, Fukuoka M, Takifuji N, Sakai N, Ryu S, Masuda N, Matsui K, Negoro S, Kusunoki Y, Tsubura E. [Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method]. Gan To Kagaku Ryoho. 1988 Nov;15(11):3095-101. Japanese. PubMed PMID: 3142367.

74: Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun. 1988 Jun 30;153(3):959-66. PubMed PMID: 2898941.

75: Fujita F, Fujita M, Yamauchi T, Sakamoto Y, Shimozuma K, Inaba H, Taguchi T. [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1297-304. Japanese. PubMed PMID: 2953311.

76: Fukui H, Ide H, Hanyu F, Ikemoto H, Okushima N, Murata Y, Sato Y, Yamada A. [A 6-day subrenal capsule assay for predictive testing of primary esophageal cancers]. Gan To Kagaku Ryoho. 1987 Apr;14(4):1106-10. Japanese. PubMed PMID: 2436579.

77: Bhushana Rao KS, Collard MP, Trouet A. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review). Anticancer Res. 1985 Jul-Aug;5(4):379-86. Review. PubMed PMID: 3898995.

78: Yoshihara T, Niimoto M, Hirai T, Miyoshi Y, Ohtagaki S, Hattori T. [Combination chemotherapy with cis-diamminedichloroplatinum (CDDP) and other anticancer agents for patients with advanced esophageal cancer]. Gan To Kagaku Ryoho. 1985 Jun;12(6):1286-93. Japanese. PubMed PMID: 2408579.

79: Gupta RS. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep. 1985 May;69(5):515-21. PubMed PMID: 2860971.

80: Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol. 1985;14(2):104-7. PubMed PMID: 3971474.

81: Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JR, Embleton MJ, Gore VA, Hellström I, Hellström KE, Jacobs E, et al. Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother. 1985;19(1):1-7. PubMed PMID: 3844970.

82: Kanzawa F, Matsushima Y, Hoshi A, Shimizu E, Saijo N, Miyazawa N. Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. Invest New Drugs. 1985;3(4):341-7. PubMed PMID: 3003004.

83: Herman TS. Effect of temperature on the cytotoxicity of vindesine, amsacrine, and mitoxantrone. Cancer Treat Rep. 1983 Nov;67(11):1019-22. PubMed PMID: 6688965.

84: Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. Review. PubMed PMID: 6189661.

85: Inoue K, Fujimoto S, Ogawa M. Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother Pharmacol. 1983;10(3):182-6. PubMed PMID: 6305523.

86: Vats TS, Mehta P, Trueworthy RC, Smith SD, Klopovich P. Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia. Cancer. 1981 Jun 15;47(12):2789-92. PubMed PMID: 6942907.

87: Salmon SE, Meyskens FL Jr, Alberts DS, Soehnlen B, Young L. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):1-12. PubMed PMID: 7226159.